Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SMARCB1 Negative”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04416568
What this trial is testing

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Who this might be right for
Malignant Rhabdoid TumorRhabdoid Tumor of the KidneyEpithelioid Sarcoma+4 more
Dana-Farber Cancer Institute 45
Early research (Phase 1)Study completedNCT02601937
What this trial is testing

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Who this might be right for
Rhabdoid TumorsINI1-negative TumorsSynovial Sarcoma+1 more
Epizyme, Inc. 109
Testing effectiveness (Phase 2)Study completedNCT02601950
What this trial is testing

Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Who this might be right for
Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)Atypical Teratoid Rhabdoid Tumors (ATRT)+8 more
Epizyme, Inc. 267
Testing effectiveness (Phase 2)Looking for participantsNCT05407441
What this trial is testing

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Who this might be right for
Atypical Teratoid Rhabdoid TumorINI1 (SMARCB1)-Deficient Primary CNS Malignant TumorsSMARCA4-deficient Primary CNS Malignant Tumors+4 more
Susan Chi, MD 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587662
What this trial is testing

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Metastatic Kidney Medullary CarcinomaMetastatic Renal Cell CarcinomaSMARCB1 Negative+2 more
M.D. Anderson Cancer Center 30